The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.51
Bid: 3.02
Ask: 4.00
Change: 0.00 (0.00%)
Spread: 0.98 (32.45%)
Open: 3.51
High: 0.00
Low: 0.00
Prev. Close: 3.51
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

30 Sep 2014 07:00

RNS Number : 9286S
Proteome Sciences PLC
30 September 2014
 



 

 

 

 

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Appointment of new Finance Director

 

30th September, 2014 - The Board of Proteome Sciences is pleased to announce the appointment of Mr. Geoffrey Ellis as Finance Director with effect from 1st October. Mr. Geoffrey John Ellis, 53, is a chartered accountant with over 30 years' experience in a range of senior financial, operational, sales and business development roles. He spent 15 years at Walt Disney where he was Chief Financial Officer of the Network of Disney Channels in EMEA and Managing Director of Disney Chanel Scandinavia, Middle East and Emerging Markets.

In addition to a strong financial background, he brings considerable international sales, marketing and licensing expertise and a key part of his role will be managing and expanding our commercial sales and marketing in USA and Europe.

Mr. James Malthouse will remain as a director of the company until his retirement on 30th November, 2014.

Mr. Ellis was a director of Curzon ISC Limited until shortly before it was placed into voluntary liquidation in March 2011. He was also a director of Warren Close Residents Association (Esher) Limited at the time it was placed into voluntary liquidation in May 2013.

Other than disclosed above, the Company confirms that there is no further information required to be disclosed in accordance with paragraph (g) of Schedule 2 of the AIM Rules.

 

- Ends -

For further information please contact:

Proteome Sciences plc

Christopher Pearce, Executive Chairman

Dr. Ian Pike, Chief Operating Officer Tel: +44 (0)1932 865065

James Malthouse, Finance Director

 

Cenkos - Nominated Adviser

Stephen Keys/Mark Connelly /Callum Davidson Tel: +44 (0)20 7397 8900

 

finnCap - Joint Broker

Geoff Nash (Corporate Finance) Tel: +44 (0)20 7220 0500

Tony Quirke (Broking)

 

IKON Associates - Public Relations

Adrian Shaw Tel: +44 (0)1483 271291

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAVKLFLZKFFBBX
Date   Source Headline
15th Sep 20167:00 amRNSHalf-year Report
28th Jul 20167:00 amRNSTrading Update and Notice of Results
24th Jun 201612:30 pmRNSAGM Statement and Result of AGM
1st Jun 20167:00 amRNSAppointment of CEO
31st May 20163:20 pmRNSPublication of Annual Report
18th May 20167:01 amRNSCEO Appointment
18th May 20167:00 amRNSPreliminary Results
5th Apr 20167:00 amRNSDeep Protein Profiling Key re. Cancer Treatment
1st Apr 20168:04 amRNSBlock Admission return
29th Feb 20167:00 amRNSTrading Update
5th Jan 20169:43 amRNSDirector Dealing
14th Dec 20154:02 pmRNSDirector Dealing
14th Dec 20159:36 amRNSHolding(s) in Company
5th Nov 20157:00 amRNSClinical Trial Results for CK1d
1st Oct 20157:00 amRNSBlock Admission return
30th Sep 20157:00 amRNSUnaudited Interim Results
4th Sep 20157:00 amRNSChange of Adviser
17th Jul 201512:01 pmRNSAGM Statement
13th Jul 20152:48 pmRNSHolding(s) in Company
3rd Jul 20155:03 pmRNSHolding(s) in Company
23rd Jun 20157:05 amRNSPublication of Annual Report
23rd Jun 20157:00 amRNSPlacing to raise £2.5 million
29th May 20157:00 amRNSPreliminary results
30th Mar 20154:21 pmRNSBlocklisting Interim Review
9th Mar 20157:00 amRNSTrading Statement
1st Dec 20143:15 pmRNSDirectorate Change
28th Nov 20147:00 amRNSSysQuant - Update/Contract Awards
19th Nov 20145:08 pmRNSHolding(s) in Company
12th Nov 20147:00 amRNSTrading Update
16th Oct 20147:00 amRNSDirectorate Change
1st Oct 20143:54 pmRNSDirector/PDMR Shareholding
30th Sep 20147:01 amRNSBlocklisting Interim Review
30th Sep 20147:00 amRNSDirectorate Change
30th Sep 20147:00 amRNSHalf Yearly Report
26th Sep 20147:00 amRNSCK1d Update: Toxicity Results
25th Sep 201410:08 amRNSContract with Genting TauRx Diagnostic Centre
15th Sep 20147:00 amRNSScience and Technology Award
19th Aug 20147:00 amRNSAppointment of Joint Broker
8th Jul 20145:45 pmRNSDirector/PDMR Shareholding
8th Jul 20147:00 amRNSAlzheimer's blood test study
1st Jul 20147:00 amRNSDirectorate Change
30th Jun 20144:42 pmRNSResult of AGM
9th Jun 20144:18 pmRNSAnnual Financial Report
29th May 20147:00 amRNSPreliminary results
1st Apr 20147:00 amRNSBlocklisting Interim Review
27th Mar 20147:00 amRNSPancreatic Cancer Study in PLOS ONE
3rd Mar 20144:25 pmRNSDirectorate Change
28th Feb 20143:46 pmRNSHolding(s) in Company
24th Feb 20147:00 amRNSPlacing
7th Feb 20147:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.